NCT07324798 Adaptive Radiotherapy for Genitourinary Cancers
| NCT ID | NCT07324798 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Prostate Cancer (Post Prostatectomy) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-12-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are: Does adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy? Participants will: Undergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion
Eligibility Criteria
Inclusion Criteria: * Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy; * Age ≥ 18 years; * ECOG performance status score 0-2; * No prior radiotherapy history within the current radiation field; * No contraindications for MRI scanning; * No contraindications for radiotherapy. Exclusion Criteria: * Patients with contraindications to radiotherapy; * Patients unable to tolerate MRI or with contraindications to MRI scanning.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07324798 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer (Post Prostatectomy). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07324798 currently recruiting?
Yes, NCT07324798 is actively recruiting participants. Contact the research team at ningninglu09@163.com for enrollment information.
Where is the NCT07324798 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07324798 clinical trial?
NCT07324798 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.